David Reardon
Hematology & Oncology · Boston, MANPI 1790869691
Payments from drug & device makers
Across 170 payments — averaging $70,746 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$10.1M
- E.r. Squibb & Sons, L.L.C.$886K
- AstraZeneca$357K
- Sumitomo Pharma America, Inc.$223K
- Janssen Research & Development, LLC$143K
- Bristol Myers Squibb$84K
- plus $225K from 22 others
Across 1 payment — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
What the payments were for
- Consulting fees$72,68191%
- Speaking & faculty fees$1,8032%
- Travel & lodging$2,8854%
- Food & beverage$1,6582%
- Charitable contribution$5001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 49 | $10,108,814 |
| E.r. Squibb & Sons, L.L.C. | 28 | $885,893 |
| AstraZeneca | 6 | $357,214 |
| Sumitomo Pharma America, Inc. | 7 | $222,889 |
| Janssen Research & Development, LLC | 17 | $143,271 |
| Bristol Myers Squibb | 3 | $83,732 |
| Novartis | 4 | $48,058 |
| Genentech, Inc. | 3 | $42,068 |
| Sanofi US Services Inc. | 2 | $27,464 |
| Pfizer | 3 | $24,142 |
| Incyte Corporation | 3 | $16,738 |
| Servier Pharmaceuticals LLC | 9 | $15,073 |
| Bayer | 9 | $6,553 |
| Boehringer Ingelheim RCV GmbH & Co KG | 3 | $6,522 |
| Janssen Global Services, LLC | 1 | $6,500 |
| Boehringer Ingelheim | 1 | $6,400 |
| F. Hoffmann-la Roche AG | 1 | $4,560 |
| Amgen | 5 | $3,507 |
| Astrazeneca UK Limited | 1 | $3,250 |
| Stemline Therapeutics Inc. | 1 | $3,200 |
| Novocure Inc. | 3 | $3,087 |
| Nuvation Bio Inc. | 1 | $2,520 |
| Boehringer Ingelheim International GmbH | 2 | $1,803 |
| Biogen | 1 | $1,000 |
| Eli Lilly | 2 | $896 |
| Agios Pharmaceuticals, Inc. | 1 | $750 |
| Insightec,inc | 2 | $741 |
| Telix Pharmaceuticals | 2 | $112 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,026,757 in reported general payments places this provider in the 95th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocortisone | 13 | $371 |
| Dexamethasone | 18 | $370 |
| Ondansetron Hcl | 15 | $201 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Boston
- Matthew DavidsBoston$58.6M
- Nadine TungBoston$32.4M
- Jorge CastilloBoston$31.2M
- Daniel DeangeloBoston$28.5M
- Sara TolaneyBoston$20.3M
- Paul RichardsonBoston$17.2M
- Amir FathiBoston$14.8M
- Jacqueline GarciaBoston$13.6M
- John KorethBoston$12.8M
- Panagiotis KonstantinopoulosBoston$11.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.